Ubs Asset Management Americas Inc Neoleukin Therapeutics, Inc. Transaction History

Ubs Asset Management Americas Inc

  • $345 Billion
  • Q2 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 16, 2021
BUY
$9.23 - $13.12 $95,438 - $135,660
10,340 New
10,340 $95,000
Q1 2021

May 14, 2021
SELL
$11.26 - $15.78 $167,774 - $235,122
-14,900 Closed
0 $0
Q4 2020

Mar 01, 2021
BUY
$10.17 - $14.56 $151,533 - $216,944
14,900 New
14,900 $210,000

Others Institutions Holding NLTX

# of Institutions
1
Shares Held
199K
Call Options Held
0
Put Options Held
0
View Full List

About Neoleukin Therapeutics, Inc.

NLTX Quotes by TradingView
  • Ticker NLTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 42,579,900
  • Description
  • Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of vario...
More about NLTX
Track This Portfolio

Track Ubs Asset Management Americas Inc Portfolio

Follow Ubs Asset Management Americas Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email